Vicore Pharma Financials
| VICO Stock | SEK 7.40 0.25 3.27% |
Vicore |
Please note, the imprecision that can be found in Vicore Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Vicore Pharma Holding. Check Vicore Pharma's Beneish M Score to see the likelihood of Vicore Pharma's management manipulating its earnings.
Vicore Pharma Stock Summary
Vicore Pharma competes with I Tech, Sdiptech, Vitec Software, JLT Mobile, and OptiCept Technologies. Vicore Pharma Holding AB , through its subsidiaries, operates as a biotech company. Vicore Pharma Holding AB was founded in 2000 and is based in Mlndal, Sweden. Vicore Pharma is traded on Stockholm Stock Exchange in Sweden.| Foreign Associate | UK |
| Instrument | Sweden Stock View All |
| Exchange | Stockholm Exchange |
| ISIN | SE0007577895 |
| Business Address | Kronhusgatan 11, Gothenburg, |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.vicorepharma.com |
| Phone | 46 3 17 88 05 60 |
| Currency | SEK - Swedish Kronor |
You should never invest in Vicore Pharma without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Vicore Stock, because this is throwing your money away. Analyzing the key information contained in Vicore Pharma's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Vicore Pharma Key Financial Ratios
Vicore Pharma's financial ratios allow both analysts and investors to convert raw data from Vicore Pharma's financial statements into concise, actionable information that can be used to evaluate the performance of Vicore Pharma over time and compare it to other companies across industries.Vicore Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Vicore Pharma's current stock value. Our valuation model uses many indicators to compare Vicore Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Vicore Pharma competition to find correlations between indicators driving Vicore Pharma's intrinsic value. More Info.Vicore Pharma Holding is rated first in return on equity category among its peers. It is rated first in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Vicore Pharma's earnings, one of the primary drivers of an investment's value.Vicore Pharma Holding Systematic Risk
Vicore Pharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Vicore Pharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Vicore Pharma Holding correlated with the market. If Beta is less than 0 Vicore Pharma generally moves in the opposite direction as compared to the market. If Vicore Pharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Vicore Pharma Holding is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Vicore Pharma is generally in the same direction as the market. If Beta > 1 Vicore Pharma moves generally in the same direction as, but more than the movement of the benchmark.
Vicore Pharma March 24, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Vicore Pharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Vicore Pharma Holding. We use our internally-developed statistical techniques to arrive at the intrinsic value of Vicore Pharma Holding based on widely used predictive technical indicators. In general, we focus on analyzing Vicore Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Vicore Pharma's daily price indicators and compare them against related drivers.
| Downside Deviation | 2.48 | |||
| Information Ratio | 0.029 | |||
| Maximum Drawdown | 16.91 | |||
| Value At Risk | (4.69) | |||
| Potential Upside | 5.29 |
Additional Tools for Vicore Stock Analysis
When running Vicore Pharma's price analysis, check to measure Vicore Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vicore Pharma is operating at the current time. Most of Vicore Pharma's value examination focuses on studying past and present price action to predict the probability of Vicore Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vicore Pharma's price. Additionally, you may evaluate how the addition of Vicore Pharma to your portfolios can decrease your overall portfolio volatility.